Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)
10.3760/cma.j.cn121090-20240312-00090
- VernacularTitle:高危多发性骨髓瘤诊断与治疗中国专家共识（2024年版）
- Keywords:
Multiple myeloma;
High-risk;
Diagnosis;
Treatment
- From:
Chinese Journal of Hematology
2024;45(5):430-435
- CountryChina
- Language:Chinese
-
Abstract:
High-risk multiple myeloma (HRMM) refers to patients with multiple myeloma whose overall survival time is less than 2-3 years under current standardized diagnosis and treatment. By combining various static and dynamic prognostic factors, risk stratification is performed to identify HRMM patients early and treat patients with personalized strategies, with the aim of significantly improving adverse survival outcomes in HRMM patients. Although the clinical value of HRMM has reached a consensus domestically in recent years, there still exist confusions and ambiguities in the definition, high-risk factors, risk stratification, and treatment of HRMM, necessitating standardization. In order to enhance the diagnostic and treatment capabilities of Chinese physicians in HRMM, the Professional Committee of Hematologic Malignancies of the Chinese Anti-Cancer Association (CACA) and the Multiple Myeloma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) have organized relevant experts to develop this consensus. This consensus aims to clarify the definition of HRMM, high-risk factors, and risk stratification system, and provide treatment recommendations for HRMM, thereby improving the quality of life and prognosis of Chinese HRMM patients.
